WEBULL
News
CLYM
5.44
-1.09%
-0.06
Weekly Report: what happened at CLYM last week (0202-0206)?
Weekly Report · 2d ago
Climb Bio Inc. to Participate in Major Healthcare Investor Conferences
Reuters · 6d ago
Weekly Report: what happened at CLYM last week (0126-0130)?
Weekly Report · 02/02 09:48
Weekly Report: what happened at CLYM last week (0119-0123)?
Weekly Report · 01/26 09:48
Ten new option listings and two option delistings on January 22nd
TipRanks · 01/22 13:36
Weekly Report: what happened at CLYM last week (0112-0116)?
Weekly Report · 01/19 09:52
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX)
TipRanks · 01/14 00:10
Weekly Report: what happened at CLYM last week (0105-0109)?
Weekly Report · 01/12 09:51
Climb Bio’s CLYM116 Moves Into First-in-Human Testing: What Early Investors Should Watch
TipRanks · 01/09 16:32
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 01/08 20:40
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO)
TipRanks · 01/08 20:01
Climb Bio outlines 2026 clinical milestones and cash runway
TipRanks · 01/08 12:29
Climb Bio Announces First Patients Dosed In Budoprutug PrisMN Phase 2 Trial In pMN; Anticipates Data-Rich 2026, With Initial Readouts From All Ongoing Budoprutug And CLYM116 Studies
Benzinga · 01/08 12:13
Climb Bio announces pipeline progress, priorities for FY26
TipRanks · 01/08 12:10
Climb Bio Inc. Outlines 2026 Strategy With Multiple Clinical Trial Readouts, Expanded Pipeline in Immune-Mediated Diseases, and Financial Guidance Extending Operations Into 2028
Reuters · 01/08 12:08
Climb Bio Inc. Expands Leadership Team and Board with Key Appointments
Reuters · 01/08 12:02
Climb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116
Reuters · 01/08 12:00
CLIMB BIO INC: FIRST PATIENTS DOSED IN BUDOPRUTUG PRISMN PHASE 2 TRIAL IN PMN, WITH INITIAL DATA EXPECTED SECOND HALF 2026
Reuters · 01/08 12:00
Major Insider Just Boosted Their Stake in Climb Bio
TipRanks · 01/08 02:00
RA Capital Management Reports Acquisition of Climb Bio Inc. Common Shares
Reuters · 01/07 21:56
More
Webull provides a variety of real-time CLYM stock news. You can receive the latest news about Climb Bio through multiple platforms. This information may help you make smarter investment decisions.
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).